A Study to Evaluate Food Effect on Pharmacokinetics Parameters After Administration of ONO-5920/YM529 Intermittent Formulation.
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2009
At a glance
- Drugs Minodronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2009 New trial record